Novavax Sinks on Concerns About COVID Vaccine Maker's Prospects Novavax營運出現隱憂 盤後崩跌25%

Novavax Inc's shares plunged to a three-year low on March 1, a day after the COVID-19 vaccine maker raised doubts about its ability to remain in business. 

The stock fell as much as 28.3 percent to $6.64 and ended the day down nearly 26 percent. Its Frankfurt-listed shares slumped nearly 28 percent. The company, which has its COVID-19 vaccine as the only marketed product after 35 years in business flagged significant uncertainty around its 2023 revenue, funding from the U.S. government, and pending arbitration with global vaccine alliance Gavi.

美國生技製藥業者、COVID-19疫苗製造商Novavax，公司股價在1日的盤後交易中暴跌了逾25%，已營運35年的Novavax宣布，在推廣疫苗遭到困難後，對公司繼續營運的能力有所疑慮，並打算縮減開支。